Cargando…

Factors associated with initiation and completion of the quadrivalent human papillomavirus vaccine series in an ontario cohort of grade 8 girls

BACKGROUND: Although over a hundred million dollars have been invested in offering free quadrivalent human papillomavirus (HPV) vaccination to young girls in Ontario, there continues to be very little information about its usage. In order to successfully guide future HPV vaccine programming, it is i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smith, Leah M, Brassard, Paul, Kwong, Jeffrey C, Deeks, Shelley L, Ellis, Anne K, Lévesque, Linda E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3224094/ https://www.ncbi.nlm.nih.gov/pubmed/21838921 http://dx.doi.org/10.1186/1471-2458-11-645

Ejemplares similares

Individual- and Regional-level determinants of Human Papillomavirus (HPV) vaccine refusal: the Ontario Grade 8 HPV vaccine cohort study
por: Remes, Olivia, et al.
Publicado: (2014)

Evidence of effective delivery of the human papillomavirus (HPV) vaccine through a publicly funded, school-based program: the Ontario Grade 8 HPV Vaccine Cohort Study
por: Lim, W Ting, et al.
Publicado: (2014)

The Cost-Effectiveness of Quadrivalent Human Papillomavirus Vaccination in Indonesia
por: Kosen, Soewarta, et al.
Publicado: (2017)

Exploring Facilitators and Barriers to Initiation and Completion of the Human Papillomavirus (HPV) Vaccine Series among Parents of Girls in a Safety Net System
por: O’Leary, Sean T., et al.
Publicado: (2018)

Modelling the effects of quadrivalent Human Papillomavirus (HPV) vaccination in Puerto Rico
por: Ortiz, Ana Patricia, et al.
Publicado: (2017)

The epidemiologic and economic impact of a quadrivalent human papillomavirus vaccine in Thailand
por: Termrungruanglert, Wichai, et al.
Publicado: (2021)

Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study
por: Arnheim-Dahlström, Lisen, et al.
Publicado: (2013)

Quadrivalent human papillomavirus vaccination and non-targeted infectious disease hospitalisation: Population-based self-controlled case series analysis
por: Hviid, Anders, et al.
Publicado: (2021)

Quadrivalent Human Papillomavirus Vaccine Effectiveness: A Swedish National Cohort Study
por: Leval, Amy, et al.
Publicado: (2013)

The epidemiological and economic impact of a quadrivalent human papillomavirus (hpv) vaccine in Estonia
por: Uusküla, Anneli, et al.
Publicado: (2013)

Correction: Modelling the effects of quadrivalent Human Papillomavirus (HPV) vaccination in Puerto Rico
por: Ortiz, Ana Patricia, et al.
Publicado: (2018)

Quadrivalent Human Papillomavirus Vaccine Effectiveness after 12 Years in Madrid (Spain)
por: Hernandez-Aguado, Juan J., et al.
Publicado: (2022)

A case of acute disseminated encephalomyelitis following human papillomavirus quadrivalent vaccination
por: Lee, Mina, et al.
Publicado: (2022)

Health service utilisation for anogenital warts in Ontario, Canada prior to the human papillomavirus (HPV) vaccine programme introduction: a retrospective longitudinal population-based study
por: Guerra, Fiona M, et al.
Publicado: (2016)

An Assessment of the Expected Cost-Effectiveness of Quadrivalent Influenza Vaccines in Ontario, Canada Using a Static Model
por: Chit, Ayman, et al.
Publicado: (2015)

Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model
por: Jit, Mark, et al.
Publicado: (2011)

Delayed dosing intervals for quadrivalent human papillomavirus vaccine do not reduce antibody avidity
por: Brady, Allison M., et al.
Publicado: (2020)

Rotavirus vaccine coverage and factors associated with uptake using linked data: Ontario, Canada
por: Wilson, Sarah E., et al.
Publicado: (2018)

Twenty Years of Medically-Attended Pediatric Varicella and Herpes Zoster in Ontario, Canada: A Population-Based Study
por: Wormsbecker, Anne E., et al.
Publicado: (2015)

A case–control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events
por: Geier, David A., et al.
Publicado: (2014)

Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants
por: Garland, Suzanne M., et al.
Publicado: (2022)

Association between quadrivalent human papillomavirus vaccination and selected syndromes with autonomic dysfunction in Danish females: population based, self-controlled, case series analysis
por: Hviid, Anders, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of the Bivalent and Quadrivalent Human Papillomavirus Vaccines from a Societal Perspective in Colombia
por: Aponte-González, Johanna, et al.
Publicado: (2013)

Prevention of Anal Condyloma with Quadrivalent Human Papillomavirus Vaccination of Older Men Who Have Sex with Men
por: Swedish, Kristin A., et al.
Publicado: (2014)

1050 Evaluation of syncope and related events following vaccination with quadrivalent human papillomavirus vaccine (2006-2013)
por: Lievano, Fabio, et al.
Publicado: (2014)

Risk of Oral Human Papillomavirus Infection Among Sexually Active Female Adolescents Receiving the Quadrivalent Vaccine
por: Schlecht, Nicolas F., et al.
Publicado: (2019)

Resolution of Harada disease-like uveitis after quadrivalent human papillomavirus vaccination: a case report
por: Kong, Kangjie, et al.
Publicado: (2021)

Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial
Publicado: (2010)

Rubella immunity among prenatal women in Ontario, 2006–2010
por: Lim, Gillian H, et al.
Publicado: (2013)

Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience
por: Garland, Suzanne M., et al.
Publicado: (2016)

Anogenital human papillomavirus virus DNA and sustained response to the quadrivalent HPV vaccine in women living with HIV-1
por: Cespedes, Michelle S., et al.
Publicado: (2018)

A delayed dose of quadrivalent human papillomavirus vaccine demonstrates immune memory in HIV-1-infected men
por: Ellsworth, G.B., et al.
Publicado: (2018)

Can quadrivalent human papillomavirus prophylactic vaccine be an effective alternative for the therapeutic management of genital warts? an exploratory study
por: Choi, Hoon
Publicado: (2019)

Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with juvenile dermatomyositis: a real-world multicentre study
por: Grein, Ingrid Herta Rotstein, et al.
Publicado: (2020)

Adjuvant-containing control arms in pivotal quadrivalent human papillomavirus vaccine trials: restoration of previously unpublished methodology
por: Doshi, Peter, et al.
Publicado: (2020)

Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50–64 Years of Age
por: Poder, Airi, et al.
Publicado: (2023)

The shifting epidemiology and serotype distribution of invasive pneumococcal disease in Ontario, Canada, 2007-2017
por: Wijayasri, Shinthuja, et al.
Publicado: (2019)

Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis
por: Kulasingam, Shalini L, et al.
Publicado: (2008)

Prevention of cervical, vaginal, and vulval cancers: role of the quadrivalent human papillomavirus (6, 11, 16, 18) recombinant vaccine
por: Diaz, Maria Lina
Publicado: (2010)

Quantifying the broader economic consequences of quadrivalent human papillomavirus (HPV) vaccination in Germany applying a government perspective framework
por: Kotsopoulos, Nikolaos, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_fh5j2lv7tg30iekmmhcghcm2fv